Full Press Release Details
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha.
IMMP
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Key Takeaway: Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Price reaction · baseline $2.28 (2022-12-06 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-2.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)